We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ALUNBRIG (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ALUNBRIG
Date registered
Evaluation commenced
Decision date
Approval time
190 working days (255)
Active ingredients
brigatinib
Registration type
NCE/NBE
Indication
ALUNBRIG (film-coated tablet) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. The approval of this medicine is based on objective response rate and duration of response in a non-comparative study.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.